Profiles

Keywords
Last Name
Institution

Marta Batus

Concepts (133)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Sarcoma
9
2023
76
3.130
Why?
Antineoplastic Agents
8
2016
244
1.960
Why?
Lung Neoplasms
14
2021
745
1.810
Why?
Carcinoma, Non-Small-Cell Lung
13
2021
372
1.510
Why?
Soft Tissue Neoplasms
2
2022
28
1.050
Why?
Molecular Targeted Therapy
3
2013
35
0.970
Why?
Metastasectomy
1
2021
5
0.860
Why?
Bone Neoplasms
3
2022
118
0.810
Why?
Antibodies, Monoclonal
4
2016
293
0.790
Why?
Immunotherapy
3
2021
75
0.760
Why?
Antineoplastic Combined Chemotherapy Protocols
6
2019
378
0.680
Why?
Medical Oncology
1
2016
37
0.570
Why?
Chemoradiotherapy
4
2019
72
0.540
Why?
Retrospective Studies
16
2023
3835
0.480
Why?
ErbB Receptors
4
2018
79
0.470
Why?
Prognosis
9
2023
1011
0.460
Why?
Melanoma
1
2013
64
0.450
Why?
Humans
27
2023
32988
0.340
Why?
Neoplasm Staging
10
2022
457
0.330
Why?
Survival Rate
5
2021
443
0.320
Why?
Mutation
3
2021
464
0.300
Why?
Carcinoma, Squamous Cell
4
2018
207
0.280
Why?
Neutrophils
2
2023
139
0.260
Why?
Drug Resistance, Neoplasm
2
2018
81
0.250
Why?
Neoplasm Recurrence, Local
2
2016
244
0.240
Why?
Receptor, IGF Type 1
2
2013
21
0.230
Why?
Sarcoma, Synovial
1
2022
3
0.220
Why?
Quinazolines
2
2012
28
0.220
Why?
High-Throughput Nucleotide Sequencing
1
2021
42
0.210
Why?
Female
16
2021
18423
0.210
Why?
Male
15
2021
17726
0.210
Why?
Pneumonectomy
1
2021
94
0.200
Why?
Lung
1
2021
179
0.200
Why?
Autoantibodies
1
2021
119
0.190
Why?
Adenocarcinoma
3
2018
231
0.190
Why?
Middle Aged
11
2021
11219
0.190
Why?
Treatment Outcome
8
2021
4036
0.170
Why?
Inflammation Mediators
1
2018
97
0.160
Why?
Survival Analysis
5
2021
372
0.150
Why?
Palliative Care
2
2015
158
0.150
Why?
Protein Kinase Inhibitors
2
2018
58
0.140
Why?
Neoplasm Metastasis
2
2013
120
0.130
Why?
Gene Dosage
2
2012
26
0.130
Why?
Adult
7
2022
9848
0.130
Why?
Radiotherapy, Conformal
1
2014
24
0.120
Why?
Aged
10
2019
10542
0.120
Why?
Cancer Vaccines
1
2013
16
0.120
Why?
Angiogenesis Inhibitors
1
2013
23
0.120
Why?
Neoplasms
1
2016
280
0.120
Why?
Forecasting
1
2013
136
0.110
Why?
Weight Gain
1
2012
75
0.110
Why?
Follow-Up Studies
5
2018
2053
0.110
Why?
PTEN Phosphohydrolase
1
2011
13
0.110
Why?
Fluorodeoxyglucose F18
2
2022
40
0.110
Why?
Phosphatidylinositol 3-Kinases
1
2011
51
0.100
Why?
Gene Amplification
1
2010
24
0.100
Why?
Child, Preschool
1
2013
798
0.100
Why?
Pyrimidines
1
2010
26
0.100
Why?
Gastrointestinal Stromal Tumors
1
2010
9
0.100
Why?
Xanthine Dehydrogenase
1
2010
7
0.100
Why?
Rectal Neoplasms
1
2010
29
0.100
Why?
Adolescent
2
2016
2687
0.100
Why?
Young Adult
2
2016
2287
0.100
Why?
Lymphocytes
2
2023
116
0.090
Why?
Gene Expression Regulation, Neoplastic
1
2010
126
0.090
Why?
Piperazines
1
2010
96
0.090
Why?
United States
1
2016
2632
0.090
Why?
Clinical Trials as Topic
1
2010
368
0.090
Why?
Lymphohistiocytosis, Hemophagocytic
1
2008
8
0.080
Why?
Child
1
2013
1634
0.080
Why?
Chromosomes, Human, Pair 10
1
2007
7
0.080
Why?
Chromosomes, Human, Pair 3
1
2007
8
0.080
Why?
Chromosomes, Human, Pair 1
1
2007
15
0.080
Why?
Receptor, ErbB-2
1
2007
47
0.080
Why?
Carcinoma, Large Cell
2
2018
18
0.070
Why?
Animals
2
2013
5371
0.070
Why?
Prospective Studies
2
2023
2002
0.070
Why?
Neoadjuvant Therapy
2
2019
62
0.070
Why?
Kaplan-Meier Estimate
2
2017
216
0.060
Why?
Etoposide
2
2015
64
0.060
Why?
Carboplatin
2
2015
54
0.060
Why?
Paclitaxel
2
2015
79
0.060
Why?
Tumor Microenvironment
1
2023
17
0.060
Why?
Lymphocyte Count
1
2023
38
0.060
Why?
Aged, 80 and over
4
2018
5249
0.060
Why?
Breast Neoplasms
1
2007
435
0.060
Why?
Time-to-Treatment
1
2022
37
0.050
Why?
Radiopharmaceuticals
1
2022
57
0.050
Why?
Positron-Emission Tomography
1
2022
102
0.050
Why?
Antigens, Neoplasm
1
2021
44
0.050
Why?
Programmed Cell Death 1 Receptor
1
2021
24
0.050
Why?
Observer Variation
1
2021
142
0.050
Why?
Cohort Studies
2
2015
2077
0.050
Why?
Mesna
1
2019
3
0.040
Why?
Ifosfamide
1
2019
11
0.040
Why?
Patient Selection
1
2021
261
0.040
Why?
Organ Sparing Treatments
1
2019
11
0.040
Why?
Doxorubicin
1
2019
60
0.040
Why?
Leg
1
2019
55
0.040
Why?
Arm
1
2019
83
0.040
Why?
Proteomics
1
2018
90
0.040
Why?
Tomography, X-Ray Computed
2
2014
899
0.040
Why?
Leukocyte Count
1
2017
96
0.040
Why?
Taxoids
1
2016
17
0.040
Why?
Deoxycytidine
1
2016
36
0.040
Why?
Time Factors
1
2022
1873
0.040
Why?
Body Weight
1
2017
167
0.040
Why?
Radiation Pneumonitis
1
2015
4
0.040
Why?
Hemoptysis
1
2015
9
0.040
Why?
Esophagitis
1
2015
11
0.040
Why?
Cough
1
2015
13
0.040
Why?
Chest Pain
1
2015
23
0.040
Why?
Chemoradiotherapy, Adjuvant
1
2015
20
0.040
Why?
Dyspnea
1
2015
39
0.030
Why?
Radiation Injuries
1
2015
44
0.030
Why?
Disease-Free Survival
1
2015
228
0.030
Why?
Mobility Limitation
1
2015
99
0.030
Why?
Radiotherapy Dosage
1
2014
147
0.030
Why?
Radiotherapy Planning, Computer-Assisted
1
2014
77
0.030
Why?
Diet
1
2015
228
0.030
Why?
Class I Phosphatidylinositol 3-Kinases
1
2011
11
0.030
Why?
Activities of Daily Living
1
2015
515
0.030
Why?
Immunohistochemistry
1
2012
471
0.020
Why?
Benzamides
1
2010
19
0.020
Why?
Colectomy
1
2010
32
0.020
Why?
Combined Modality Therapy
1
2011
449
0.020
Why?
Biopsy
1
2010
277
0.020
Why?
Quality of Life
1
2015
747
0.020
Why?
Smoking
1
2010
206
0.020
Why?
Signal Transduction
1
2012
590
0.020
Why?
Fatal Outcome
1
2008
76
0.020
Why?
Risk Assessment
1
2011
814
0.020
Why?
Antibodies, Monoclonal, Humanized
1
2007
132
0.020
Why?
Batus's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description